Bacterial lysates as immunostimulants for respiratory infection in children: mechanism of action, efficacy and safety


如何引用文章

全文:

详细

The relevance of the use of immunostimulants in the complex treatment of acute and recurrent respiratory infections is beyond doubt. At the same time, a number of factors: unexplored mechanism of action, lack of evidence of efficacy, unexplored safety - inhibit the widespread use of many immunostimulants. In contrast to bacterial lysates, in particular the drug OM-85 (Broncho-Munal®), on the contrary, there are reliable data on good efficacy against both acute and recurrent respiratory infections, evidence of safety and scientific information on the mechanism of action.

全文:

受限制的访问

作者简介

Mikhail Shevyakov

Mechnikov North-Western State Medical University

Email: shevyakov@inbox.ru
Saint Petersburg, Russia

参考

  1. Урсова Н.И. Дисбактериозы кишечника в детском возрасте: инновации в диагностике коррекции и профилактике. Руководство для врачей. М., 2013.
  2. Косенко И.М. Иммуномодулирующая терапия заболеваний ротоглотки у детей. Детские инфекции. 2010; 9 (1): 56-61.
  3. Согласованное мнение экспертов IX Образовательного международного консенсуса по респираторной медицине в педиатрии по вопросам применения бактериальных лизатов в педиатрической практике. Под ред. Н.А. Геппе, А.Б. Малахова. Доктор.РУ. Педиатрия. 2020; 19 (3): 61-3.
  4. Kearney SC et al. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol 2015; 114 (5): 364-9.
  5. Zagar S, Lofler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a doubleblind clinical trial. J Otorhinolaryngol Relat Spec 1988; 50 (6): 397-404.
  6. Dang AT et al. OM-85 is an immunomodulator of interferon-b production and in-flammasome activity. Sci Rep 2017; 7 (43844).
  7. Liu YW, Dong SH, Zhan GY et al. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis. Eur Rev Med Pharmacol Sci 2017; 21 (14): 3332-6.
  8. Rossi GA et al. Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice. Italian J Pediatrics 2018; 44 (1): 112.
  9. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJL. Immunostimulants for preventing respiratory tract infection in children (Review). A reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library. 2011; 6. http://www.thecochranelibrary.com
  10. Esposito S et al. Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study. Int J Environmental Res Public Health 2019; 16 (6): 1065.
  11. Esposito S et al. A randomized placebo-controlled double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Trans Med 2019; 17 (1): 284.
  12. Yin J et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol 2018; 54: 198-209.
  13. Bitar MA, Saade R. The role of OM-85 BV (Broncho-Vaxom) in preventing recurrent acute tonsillitis in children. Int J Pediatr Otorhinolaryngol 2013; 77 (5): 670-3.
  14. Sorokman TV, Moldovan PM, Popeliuk NO et al. Clinical and Immunological Efficacy of OM-85 Bacterial Lysate In Children With Respiratory Tract Infection. Actual Infectology 2020; 8: 18-24. doi: 10.22141/2312-413x.8.2.2020.199731
  15. Berber A, Del-Rio-Navarro BE. Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections in children that attend day-care centers. Health Econ Rev 2019; 9 (1): 12.
  16. Bodemer C et al. Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study PloS One 2017; 12 (3): e0161555.
  17. Triantafillou V et al. Broncho VaxomR (OM 85 BV) soluble components stimulate sinonasal innate immunity. Int Forum Allergy Rhinol 2019.
  18. Геппе Н.А. и др. Острые инфекции дыхательных путей у детей. Диагностика, лечение и профилактика: клиническое руководство. М.: МЕдКом-Про, 2018.
  19. Fokkens WJ et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology 2020.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Consilium Medicum, 2020

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.